Trump Nominates White House Aide to Lead FDA

The update

President Trump has announced his intent to nominate Dr. Heidi Overton, a physician and deputy assistant to the president for domestic policy, to serve as the next commissioner of the Food and Drug Administration. Overton, who previously worked as a White House fellow during Trump’s first term, has been closely aligned with Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz. The nomination comes as the agency faces a leadership vacuum following the resignation of former Commissioner Marty Makary in May.

Why it matters

This appointment signals a potential shift in regulatory strategy for the FDA, an agency currently grappling with internal staff departures and a turbulent leadership transition. Overton’s role in recent White House health initiatives suggests she will prioritize the administration’s stated goals of accelerating drug approvals, lowering drug prices, and reforming clinical trials. Her confirmation will be a key test for the Senate, as she steps into a role overseeing critical decisions on food safety, drug regulation, and medical devices.

What to watch

• Senate confirmation: Overton will need to be confirmed by the Senate before assuming the role.
• Regulatory priorities: Watch for how she approaches current FDA policies, particularly regarding childhood vaccines and flavored e-cigarettes, which were points of contention for her predecessor.
• Staff stability: The FDA has seen a significant exodus of top staff; her ability to stabilize the agency will be closely monitored.

Sources

• cbsnews.com — Overton's background, role, and confirmation process.
• thehill.com — Confirmation of the nomination and context on the agency's current state.